Stay updated with breaking news from Danielc Cattran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with... | May 12, 2023
/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa's distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e...